A Phase 2 interventional study of Placebo and rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 24 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-24.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 53rd largest by enrollment, is one of 2 that started in 2009, is one of 11 in phase 2, and was the 24th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 121st largest by enrollment of the 141 interventional ones that give a count, is one of 22 that started in 2009, is one of 20 in phase 2, and was the 57th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate. In Part 1 of the study, patients will be randomized to receive either MabThera 0.5g iv or placebo on days 1 and 15, follo wed by RoActemra at one of the ascending doses between 2mg/kg and 8mg/kg at week s 4, 8 and 12 (MabThera arm) or 8mg/kg (placebo arm). In Part 2, additional pati ents will be randomized to one of 2 groups to receive MabThera 0.5g on days 1 an d 15 followed by the selected dose (from Part 1)of RoActemra at weeks 4, 8 and 1 2, or placebo on days 1 and 15 followed by RoActemra 8mg/kg at weeks 4,8 and 12.
All patients will then be eligible to receive extension treatment withRoActemra every 4 weeks. The anticipated time on study treatment is 12 months, and the tar get sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: tocilizumab [RoActemra/Actemra]
Drug: Placebo · Drug: tocilizumab [RoActemra/Actemra]
iv on days 1 and 15 (Parts 1 and 2)
Drug page: Rituximab
0.5g iv on days 1 and 15 (Parts 1 and 2)
Drug page: Tocilizumab
2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
Percentage of Participants Achieving Low Disease Activity (LDA) at Week 16 Assessed Using Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR)
The Disease Activity Score based on 28 joint count (DAS28) and Erythrocyte Sedimentation Rate (ESR), is a measure of the participant's disease activity. It is based on the Tender Joint Count (TJC \[28 joints\]), Swollen Joint Count (SJC \[28 joints\]), participant's global assessment of disease activity (PtGA) Visual Analog Scale (VAS) in millimeters (mm), and ESR in millimeters per hour (mm/hour). DAS28-ESR scores range from 0 - 10. Definition of LDA was based on DAS28-ESR scores. To achieve LDA the DAS28-ESR had to be (less than or equal to) ≤ 3.2. DAS28-ESR equals (=) (0.56 times (\*) (square root)√ TJC plus (+) (0.28 \* √ SJC + (0.70 \* ln(ESR))+(0.014 \* (Global Health) GH) Where: TJC = based on 28 joints SJC = based on 28 joints ESR = erythrocyte sedimentation rate in mm/hour GH = participant's global assessment of disease activity ln = natural log
Time frame: Week 16
Percentage of Participants Achieving Remission at Week 16 Assessed Using DAS28-ESR
The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR less than (\<) 2.6
Time frame: Week 16
Percentage of Participants by European League Against Rheumatism (EULAR) Response Category at Week 16
DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline (greater than) \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or DAS28-ESR \>5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; nonresponders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.
Time frame: Week 16
Change From Baseline in DAS28-ESR
The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR scores were calculated as follows: DAS28-ESR = (0.56 \* √TJC)+(0.28 \* √SJC)+(0.70 \* ln(ESR))+(0.014 \* GH). No imputation used for tender and swollen joint counts, ESR, and patient's global assessment of disease activity VAS.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48
Clinical Disease Activity Index Scores
The Clinical Disease Activity Index (CDAI) score was calculated according to the following formula: CDAI = SJC + TJC + GH/10 + EGA/10 Where: SJC = swollen joint count based on 28 joints; TJC = tender joint count based on 28 joints; GH = Participant's global assessment of disease activity; EGA = evaluator's (physician's) global assessment of disease activity. CDAI scores range from 0-76 and the following cut-off points for different disease activity states have been used: high disease activity \>22; moderate disease activity \>10 and ≤22; LDA \>2.8 and ≤10; and remission ≤ 2.8. No imputation used for TJC, SJC, Patient's Global Assessment of Disease Activity VAS and Physicians global assessment of disease activity VAS.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48
Simplified Disease Activity Index (SDAI) Scores
The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), Participant and Physician assessed global disease activity (assessed on 0-100 mm VAS; higher scores = greater affection due to disease activity), and ESR (mm/hour). SDAI total score ranged from 0 to 86. Higher scores indicated greater disease activity.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
Change From Baseline to Week 48 in SJC and TJC
An assessment of 28 joints for swelling and tenderness will be made. Joints will be assessed and classified as swollen (1)/not swollen (0) and tender(1)/not tender (0) by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. The 28 joints assessed comprise shoulders (2 joints), elbows (2 joints), wrists (2 joints), metacarpophalangeal joints on digits 1-5 (10 joints), interphalangeal on digit 1 (2 joints), proximal interphalangeal joints on digits 2-5 (8 joints), and knees (2 joints).
Time frame: Baseline and Week 48
Change From Baseline to Week 48 in Health Assessment Questionnaire (HAQ)
The Stanford Health Assessment Questionnaire disability index specific for rheumatoid arthritis was completed by the participants for efficacy assessments.
Time frame: Baseline and Week 48
Change From Baseline to Week 48 in C-Reactive Protein (CRP)
CRP is an acute phase reactant and is a measure of inflammation.
Time frame: Baseline and Week 48
Change From Baseline to Week 48 in ESR
ESR is an acute phase reactant and is a measure of inflammation.
Time frame: Baseline and Week 48
Change From Baseline to Week 48 in Physician's Global Assessment of Disease Activity
Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm= maximum disease activity. The physician marked the line according to their assessment and the distance from the left edge was measured.
Time frame: Baseline and Week 48
Change From Baseline to Week 48 in Participant's Global Assessment of Disease Activity
Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm = maximum disease activity. The participant marked the line according to their assessment and the distance from the left edge was measured.
Time frame: Baseline and Week 48
Change From Baseline to Week 48 in Participant's Assessment of Pain
Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no pain and 100 mm = maximum pain. The participant marked the line according to their assessment and the distance from the left edge was measured.
Time frame: Baseline and Week 48
| Milestone | Placebo + Tocilizumab (TCZ) 8 Milligrams Per Kilogram (mg/kg) | Rituximab (0.5 Grams [g]) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Started | 4 | 10 | 10 |
| Completed | 3 | 7 | 10 |
| Not completed | 1 | 3 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Milestone | Placebo + Tocilizumab (TCZ) 8 Milligrams Per Kilogram (mg/kg) | Rituximab (0.5 Grams [g]) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Started | 3 | 9 | 12 |
| Completed | 2 | 9 | 12 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Milestone | Placebo + Tocilizumab (TCZ) 8 Milligrams Per Kilogram (mg/kg) | Rituximab (0.5 Grams [g]) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Started | 2 | 5 | 7 |
| Completed | 2 | 5 | 0 |
| Not completed | 0 | 0 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 7 |
The Disease Activity Score based on 28 joint count (DAS28) and Erythrocyte Sedimentation Rate (ESR), is a measure of the participant's disease activity. It is based on the Tender Joint Count (TJC \[28 joints\]), Swollen Joint Count (SJC \[28 joints\]), participant's global assessment of disease activity (PtGA) Visual Analog Scale (VAS) in millimeters (mm), and ESR in millimeters per hour (mm/hour). DAS28-ESR scores range from 0 - 10. Definition of LDA was based on DAS28-ESR scores. To achieve LDA the DAS28-ESR had to be (less than or equal to) ≤ 3.2. DAS28-ESR equals (=) (0.56 times (\*) (square root)√ TJC plus (+) (0.28 \* √ SJC + (0.70 \* ln(ESR))+(0.014 \* (Global Health) GH) Where: TJC = based on 28 joints SJC = based on 28 joints ESR = erythrocyte sedimentation rate in mm/hour GH = participant's global assessment of disease activity ln = natural log
| percentage of participants | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) at Week 16 Assessed Using Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) | 50.0 | 11.1 | 20.0 |
The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR less than (\<) 2.6
| percentage of participants | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Percentage of Participants Achieving Remission at Week 16 Assessed Using DAS28-ESR | 0.0 | 0.0 | 10.0 |
DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline (greater than) \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or DAS28-ESR \>5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; nonresponders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.
| percentage of participants | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| No Response | 0.0 | 22.2 | 11.1 |
| Moderate Response | 50.0 | 66.7 | 66.7 |
| Good Response | 50.0 | 11.1 | 22.2 |
The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR scores were calculated as follows: DAS28-ESR = (0.56 \* √TJC)+(0.28 \* √SJC)+(0.70 \* ln(ESR))+(0.014 \* GH). No imputation used for tender and swollen joint counts, ESR, and patient's global assessment of disease activity VAS.
| units on a scale | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Week 4 (n=4,9,10) | -1.9 ± 1.73 | -0.7 ± 1.44 | -1.0 ± 0.72 |
| Week 8 (n=4,10,10) | -2.7 ± 0.55 | -0.5 ± 1.33 | -1.9 ± 1.31 |
| Week 12 (n=4,10,9) | -2.7 ± 0.57 | -1.2 ± 1.60 | -2.3 ± 1.36 |
| Week 16 (n=4,9,9) | -3.0 ± 0.80 | -1.8 ± 1.44 | -2.3 ± 1.25 |
| Week 20 (n=4,9,9) | -3.6 ± 0.70 | -2.2 ± 1.16 | -2.7 ± 1.45 |
| Week 24 (n=4,9,8) | -3.5 ± 1.28 | -2.2 ± 1.14 | -2.9 ± 1.34 |
| Week 32 (n=4,9,8) | -2.6 ± 1.62 | -3.1 ± 1.92 | -3.3 ± 1.83 |
| Week 40 (n=3,8,8) | -2.6 ± 1.24 | -2.2 ± 1.63 | -2.7 ± 1.02 |
| Week 48 (n=4,8,7) | -3.3 ± 1.84 | -2.9 ± 1.50 | -3.0 ± 1.24 |
The Clinical Disease Activity Index (CDAI) score was calculated according to the following formula: CDAI = SJC + TJC + GH/10 + EGA/10 Where: SJC = swollen joint count based on 28 joints; TJC = tender joint count based on 28 joints; GH = Participant's global assessment of disease activity; EGA = evaluator's (physician's) global assessment of disease activity. CDAI scores range from 0-76 and the following cut-off points for different disease activity states have been used: high disease activity \>22; moderate disease activity \>10 and ≤22; LDA \>2.8 and ≤10; and remission ≤ 2.8. No imputation used for TJC, SJC, Patient's Global Assessment of Disease Activity VAS and Physicians global assessment of disease activity VAS.
| units on a scale | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Baseline (n=4, 10, 10) | 37.7 ± 4.59 | 36.4 ± 9.16 | 33.0 ± 7.69 |
| Week 4 (n=4, 8, 10) | 21.2 ± 14.19 | 23.4 ± 12.38 | 20.0 ± 6.97 |
| Week 8 (n=4,10,10) | 14.6 ± 4.38 | 29.4 ± 14.91 | 15.5 ± 9.96 |
| Week 12 (n=4,10, 9) | 16.3 ± 10.52 | 23.2 ± 12.47 | 13.4 ± 8.40 |
| Week 16 (n=4,10, 9) | 9.5 ± 5.70 | 19.5 ± 15.42 | 12.7 ± 8.32 |
| Week 20 (n=4, 8, 9) | 10.8 ± 4.46 | 15.4 ± 7.76 | 11.6 ± 6.64 |
| Week 24 (n=4, 9, 8) | 9.2 ± 6.71 | 12.6 ± 3.98 | 10.9 ± 5.47 |
| Week 32 (n=4, 9, 8) | 15.2 ± 10.42 | 11.5 ± 13.14 | 9.3 ± 9.42 |
| Week 40 (n=3, 8, 8) | 20.3 ± 8.35 | 17.9 ± 16.40 | 11.8 ± 5.31 |
| Week 48 (n=4, 7, 8) | 11.6 ± 10.11 | 12.8 ± 12.15 | 7.1 ± 6.41 |
The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), Participant and Physician assessed global disease activity (assessed on 0-100 mm VAS; higher scores = greater affection due to disease activity), and ESR (mm/hour). SDAI total score ranged from 0 to 86. Higher scores indicated greater disease activity.
No measurements were reported for this outcome.
An assessment of 28 joints for swelling and tenderness will be made. Joints will be assessed and classified as swollen (1)/not swollen (0) and tender(1)/not tender (0) by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. The 28 joints assessed comprise shoulders (2 joints), elbows (2 joints), wrists (2 joints), metacarpophalangeal joints on digits 1-5 (10 joints), interphalangeal on digit 1 (2 joints), proximal interphalangeal joints on digits 2-5 (8 joints), and knees (2 joints).
No measurements were reported for this outcome.
The Stanford Health Assessment Questionnaire disability index specific for rheumatoid arthritis was completed by the participants for efficacy assessments.
No measurements were reported for this outcome.
CRP is an acute phase reactant and is a measure of inflammation.
No measurements were reported for this outcome.
ESR is an acute phase reactant and is a measure of inflammation.
No measurements were reported for this outcome.
Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm= maximum disease activity. The physician marked the line according to their assessment and the distance from the left edge was measured.
No measurements were reported for this outcome.
Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm = maximum disease activity. The participant marked the line according to their assessment and the distance from the left edge was measured.
No measurements were reported for this outcome.
Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no pain and 100 mm = maximum pain. The participant marked the line according to their assessment and the distance from the left edge was measured.
No measurements were reported for this outcome.
Collected over Adverse Events were recorded throughout the study from the date of first study drug administration until 48 weeks of treatment period and for those in the Safety follow up population until the end of follow up period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + TCZ (8 mg/kg) | — | 1/3 (33.3%) | 3/3 (100%) |
| Rituximab (0.5 g) + TCZ (2 mg/kg) | — | 2/9 (22.2%) | 9/9 (100%) |
| Rituximab (0.5 g) + TCZ (4 mg/kg) | — | 3/12 (25%) | 11/12 (91.7%) |
| Event | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 1/3 | 0/9 | 0/12 |
| Infusion related reactionGeneral disorders | 0/3 | 1/9 | 0/12 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/3 | 1/9 | 0/12 |
| PneumoniaInfections and infestations | 0/3 | 1/9 | 0/12 |
| Chest painGeneral disorders | 0/3 | 0/9 | 1/12 |
| Large intestinal ulcer haemorrhageGastrointestinal disorders | 0/3 | 0/9 | 1/12 |
| Umbilical herniaGastrointestinal disorders | 0/3 | 0/9 | 1/12 |
| Event | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 0/9 | 1/12 |
| Oedema peripheralGeneral disorders | 2/3 | 1/9 | 0/12 |
| Upper respiratory tract infectionInjury, poisoning and procedural complications | 0/3 | 3/9 | 3/12 |
| NasopharyngitisInfections and infestations | 1/3 | 0/9 | 2/12 |
| Acute tonsillitisInfections and infestations | 1/3 | 0/9 | 0/12 |
| DyspepsiaGastrointestinal disorders | 0/3 | 3/9 | 0/12 |
| Infusion related reactionGeneral disorders | 0/3 | 3/9 | 1/12 |
| Back painMusculoskeletal and connective tissue disorders | 1/3 | 1/9 | 1/12 |
| Photosensitivity reactionSkin and subcutaneous tissue disorders | 1/3 | 0/9 | 0/12 |
| DizzinessNervous system disorders | 1/3 | 0/9 | 0/12 |
Safety population: All participants who were randomized and received any part of an infusion of study medication; participants who received the incorrect therapy from that intended were summarized in the group according to the therapy actually received for the majority of the time through Week 48.
| Age, Continuous(years) | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) | Total |
|---|---|---|---|---|
| Mean | 41.3 ± 11.02 | 48.2 ± 10.50 | 50.0 ± 6.97 | 48.3 ± 8.94 |
| Sex: Female, Male(Participants) | Placebo + TCZ (8 mg/kg) | Rituximab (0.5 g) + TCZ (2 mg/kg) | Rituximab (0.5 g) + TCZ (4 mg/kg) | Total |
|---|---|---|---|---|
| Female | 3 | 7 | 10 | 20 |
| Male | 0 | 2 | 2 | 4 |
The record gives a start of Mar 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab